logo
  • SELECT LICENSE :

  • US $4,299.00
  • US $8,599.00

Monoclonal Antibody Custom Service Market, By Type (Rat Custom Monoclonal Antibody, Rabbit Custom Monoclonal Antibody and Others), By Application (Diagnostic, Therapeutic, protein purification) By End User (Hospital, ASC, Cardiology Center) opportunities and forecast 2020-2027

  • DLR2216
  • 20 September, 2020
  • Pharma & Healthcare
  • Pages: 120
  • Global
Market Overview

Monoclonal Antibodies are class of the antibodies derived from single ancestral cell. The antibodies have the tendency to grow indeterminately and are very specific for location in body derived from single clone. Growing investment in R&D, increasing prevalence of the chronic infections, diseases, and rising incidence of immunological diseases are some of the key factors driving market growth. However, high price of the monoclonal antibody services are expected to hinder the growth of the market to some extent.
The service offers development of both mouse and rat hybridomas for production of custom monoclonal antibodies from the recombinant protein antigens or synthesized peptide. The services provide comprehensive services for the antibody cloning, engineering, expression, and purification in addition to the custom antibody development for the multiple biotechnological and pharmaceutical companies.

Segment Overview

The global market is segmented based on application, type, and end-users. Based on type, the market is categorized into rabbit custom monoclonal antibody, rat custom monoclonal antibody, and others.
Further, on the basis of application, market is categorised into therapeutic application, diagnostic application, and protein purification.

Regional Overview

The North America dominates the market due to the presence of well-developed technology, patient population, the presence of the leading players and high healthcare expenditure. As per the National Cancer Institute (NCI) in 2016, over 1.6 million new cases of cancer were diagnosed in the U.S.

Europe holds second position in market. It is anticipated that support provided by government bodies for R&D drives the market in the European region. Asia-Pacific is likely to be fastest growing during forecast period. The rapid growth is attributed to increasing risk of the infectious diseases in the region. Middle East and Africa (MEA) holds the least share in market due to the presence of slow developing and poor countries, especially, in the African region.

Key Players
  1. Thermo Fisher Scientific
  2. GenScript
  3. Abnova Corporation
  4. Creative-Biolabs
  5. Abcam plc
  6. ProMab Biotechnologies Inc,
  7. Envigo
  8. Precision Antibody
  9. ProteoGenix
  10. Sino Biological

Market Segmentation

By Type
  • Rat Custom Monoclonal Antibody
  • Rabbit Custom Monoclonal Antibody
  • Others.
By Application
  • Diagnostic Application
  • Therapeutic Application
  • Protein Purification
By Geography
  • North America
    • US
    • Canada
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Saudi Arabia
    • UAE
    • Rest of LAMEA


1 Report Prologue 11

    2 Introduction 15

    • 2.1 Scope of Study 15
    • 2.2 Research Objective 15
    • 2.3 Assumptions & Limitations 15
      • 2.3.1 Assumptions 15
      • 2.3.2 Limitations 15
    • 2.4 Market Structure 16

    3 Research Methodology 17

    • 3.1 Primary Research 18
    • 3.2 Secondary Research 18
    • 3.3 Market Size Estimation 18
      • 3.3.1 Market share analysis 19
    • 3.4 Market Pricing Approach 20

    4 Market Dynamics 21

    • 4.1 Introduction 21
    • 4.2 Drivers 22
      • 4.2.1 Increasing investment in research & development (weightage 45%) 22
      • 4.2.2 Increasing prevalence of chronic diseases and infection (weightage 40%) 23
      • 4.2.3 Increasing prevalence of immunological diseases (weightage 15%) 24
    • 4.3 Restraints 25
      • 4.3.1 High cost of the monoclonal antibody services 25
    • 4.4 Opportunities 26
    • 4.5 Macroeconomic Indicators 26

    5 Market Factor Analysis 28

    • 5.1 Value Chain Analysis 28
    • 5.2 Porter’s Five Forces Model 29
      • 5.2.1 Bargaining power of suppliers 29
      • 5.2.2 Bargaining power of buyers 30
      • 5.2.3 Threat of new entrants 30
      • 5.2.4 Threat of substitutes 30
      • 5.2.5 Intensity of rivalry 30
    • 5.3 Investment Opportunity Analysis 31
    • 5.4 Technology Trend Analysis 31

    6 Global Monoclonal Antibody Custom Service Market, by Type 32

    • 6.1 Introduction 32
    • 6.2 Rat Custom Monoclonal Antibody 33
    • 6.3 Rabbit Custom Monoclonal Antibody 35
    • 6.4 Others 36

    7 Global Monoclonal Antibody Custom Service Market, by Application 37

    • 7.1 Introduction 37
    • 7.2 Diagnostic Application 39
      • 7.2.1 Biochemical Analysis 39
        • 7.2.1.1 Pregnancy 39
        • 7.2.1.2 Cancer 39
        • 7.2.1.3 Hormonal Disorder 39
        • 7.2.1.4 Infectious Diseases 40
      • 7.2.2 Diagnostic Imaging 40
        • 7.2.2.1 Cardiovascular Diseases 40
        • 7.2.2.2 Cancer 41
        • 7.2.2.3 Bacterial Infections 41
  • 7.3 Therapeutic Application 42
  • 7.3.1.1 MAb as Therapeutic Agents 42
  • 7.3.1.2 MAb as Targeting Agents 42
  • 7.4 Protein Purification 44
  • 8 Global Monoclonal Antibody Custom Service Market, by End User 45

    • 8.1 Introduction 45
    • 8.2 Hospitals 47
    • 8.3 Research & Academic Laboratories 48
    • 8.4 Pharmaceutical & Biotechnology Companies 49

    9 Global Monoclonal Antibody Custom Service Market, by Region 50

    • 9.1 Introduction 50
    • 9.2 Americas 52
      • 9.2.1 US 55
      • 9.2.2 Canada 57
      • 9.2.3 South America 59
    • 9.3 Europe 62
      • 9.3.1 Germany 65
      • 9.3.2 France 67
      • 9.3.3 UK 69
      • 9.3.4 Italy 71
      • 9.3.5 Spain 73
      • 9.3.6 Rest of Western Europe 75
      • 9.3.7 Eastern Europe 77
    • 9.4 Asia Pacific 80
      • 9.4.1 Japan 83
      • 9.4.2 China 85
      • 9.4.3 India 87
      • 9.4.4 Australia 89
      • 9.4.5 Republic of Korea 91
      • 9.4.6 Rest of Asia Pacific 93
    • 9.5 Middle East & Africa 96
      • 9.5.1 Middle East 99
      • 9.5.2 Africa 101

    10 Company Landscape 104

    • 10.1 Introduction 104
    • 10.2 Company Share Analysis 104
    • 10.3 Key Developments 105

    11 Company Profiles 107

    • 11.1 Thermo Fisher Scientific 107
      • 11.1.1 Company Overview 107
      • 11.1.2 Financials 107
      • 11.1.3 Products 107
      • 11.1.4 Strategy 107
      • 11.1.5 Key Developments 107
    • 11.2 GenScript 108
      • 11.2.1 Company Overview 108
      • 11.2.2 Financials 108
      • 11.2.3 Products 108
      • 11.2.4 Strategy 108
      • 11.2.5 Key Developments 108
    • 11.3 Abnova Corporation 109
      • 11.3.1 Company Overview 109
      • 11.3.2 Financials 109
      • 11.3.3 Products 109
      • 11.3.4 Strategy 109
      • 11.3.5 Key Developments 109
    • 11.4 Creative-Biolabs 110
      • 11.4.1 Company Overview 110
      • 11.4.2 Financials 110
      • 11.4.3 Products 110
      • 11.4.4 Strategy 110
      • 11.4.5 Key Developments 110
    • 11.5 Abcam plc 111
      • 11.5.1 Company Overview 111
      • 11.5.2 Financials 111
      • 11.5.3 Products 111
      • 11.5.4 Strategy 111
      • 11.5.5 Key Developments 111
    • 11.6 ProMab Biotechnologies Inc 112
      • 11.6.1 Company Overview 112
      • 11.6.2 Financials 112
      • 11.6.3 Products 112
      • 11.6.4 Strategy 112
      • 11.6.5 Key Developments 112
    • 11.7 Envigo 113
      • 11.7.1 Company Overview 113
      • 11.7.2 Financials 113
      • 11.7.3 Products 113
      • 11.7.4 Strategy 113
      • 11.7.5 Key Developments 113

    12 Conclusion 114

    • 12.1 Key Findings 114
      • 12.1.1 CEO’s Viewpoint 114
      • 12.1.2 Unmet Needs 114
      • 12.1.3 Key Companies to Watch 114

    13 Appendix 115

    • 13.1 Discussion Blue Print 115
    • 13.2 References 117

    Report You Might be Interested